home / stock / plrz / plrz news

PLRZ News and Press, Polyrizon Ltd.

Stock Information
Company Name: Polyrizon Ltd.
Stock Symbol: PLRZ
Market: NASDAQ
Website: polyrizon-biotech.com
Menu
Get PLRZ Alerts

News, Short Squeeze, Breakout and More Instantly...
PLRZ - Polyrizon Announces Successful Results for NASARIX(TM) Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial

Raanana, Israel, July 02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced successful results from its biocomp...
PLRZ - Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial

Raanana, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, announced it has received central IRB approval to b...

PLRZ - Polyrizon receives U.S. patent publication notice for nasal drug delivery platform

2026-06-17 08:53:12 ET More on Polyrizon Ltd. Polyrizon signs MOU to acquire up to 20% stake in eVTOL firm Colugo Financial information for Polyrizon Ltd. Read the full article on Seeking Alpha For further details see: Polyrizon receives U.S. patent publi...

PLRZ - Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform

Raanana, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the publication of U.S. patent appli...
PLRZ - Polyrizon Advances NASARIX(TM) Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway

New performance and characterization study in collaboration with leading European medical center marks a critical milestone in the validation of the NASARIX™ allergy blocker’s protective barrier function Raanana, Israel, June 15, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: P...

PLRZ - Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology

Raanana, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced that the European Patent Office (EPO...

PLRZ - Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX(TM) Trial

Raanana, Israel, June 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced it has signed agreements with two ad...
PLRZ - Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX(TM) Allergy Blocker Clinical Trial

Raanana, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the signing of its first Clinical Tri...

PLRZ - Pulse Equity: Emerging Outbreaks - Polyrizon's Approach to Broad and Rapidly Deployable Protection

Pulse Equity: Emerging Outbreaks - Polyrizon's Approach to Broad and Rapidly Deployable Protection PR Newswire In light of the growing challenges posed by emerging respiratory threats, including recent Hantavirus, Polyrizon is advancing a biophysical barrier technology that may off...

PLRZ - Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform

Raanana, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the submission of amended claims in i...
Next 10